PMID: 11897858Mar 19, 2002Paper

Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed

The Journal of Physiology
David HarrisM D Randall

Abstract

The endogenous cannabinoid anandamide has recently been identified as a vasorelaxant but the underlying mechanisms are controversial. The vasorelaxant responses to anandamide have now been examined in the rat mesenteric arterial bed. Anandamide caused potent vasorelaxations (pD(2) = 6.24 +/- 0.06; R(max) = 89.4 +/- 2.2 %) which were unaffected by inhibition of nitric oxide synthase with N(G)-nitro-L-arginine methyl ester (L-NAME; 300 microM). The responses were also predominantly endothelium independent and were unaffected by the cannabinoid CB(1) receptor antagonist SR141716A (1 microM), although at higher concentrations (3 and 10 microM) SR141716A was inhibitory. Both 1 mM ouabain (pD(2) = 5.90 +/- 0.07; R(max) = 50.4 +/- 6.5 %) and 100 microM 18alpha-glycyrrhetinic acid (pD(2) = 6.04 +/- 0.14; R(max) = 40.9 +/- 5.8 %) opposed anandamide-induced vasorelaxation. However, the gap junction inhibitors carbenoxolone (100 microM) and palmitoleic acid (50 microM) did not affect vasorelaxation to anandamide. Relaxation to anandamide was significantly attenuated by both capsaicin pretreatment to deplete the sensory nerves of neurotransmitters (pD(2) = 5.86 +/- 0.18; R(max) = 56.3 +/- 5.2 %) and the vanilloid antagonist ruthenium red (...Continue Reading

References

Jan 14, 1986·Biochemical and Biophysical Research Communications·J S DavidsonE H Harley
Jul 1, 1996·British Journal of Pharmacology·P M ZygmuntE D Högestätt
Dec 4, 1996·Biochemical and Biophysical Research Communications·M D RandallD A Kendall
Sep 18, 1997·The Journal of Clinical Investigation·D G DeutschL C Moore
Jan 10, 1998·British Journal of Pharmacology·P M ZygmuntA H Weston
Feb 12, 1998·The American Journal of Physiology·P F PrattW B Campbell
Apr 16, 1998·Pain·Jennelle Durnett RichardsonKenneth M Hargreaves
Apr 29, 1998·Trends in Pharmacological Sciences·M D Randall, D A Kendall
May 26, 1998·European Journal of Pharmacology·J D RichardsonK M Hargreaves
Feb 5, 1999·Naunyn-Schmiedeberg's Archives of Pharmacology·D HarrisM D Randall
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·Z JáraiG Kunos
Jun 1, 2000·Naunyn-Schmiedeberg's Archives of Pharmacology·P M ZygmuntE D Högestätt
Oct 19, 2001·British Journal of Pharmacology·R WhiteC R Hiley

❮ Previous
Next ❯

Citations

Dec 31, 2002·Chemistry and Physics of Lipids·George KunosJudith Harvey-White
Jul 16, 2003·European Journal of Pharmacology·Vera Ralevic
Jul 27, 2002·Orvosi hetilap·Zoltán Járai, György Kúnos
Jun 28, 2003·Brain Research. Molecular Brain Research·José Martínez-OrgadoM Paz Viveros
Feb 10, 2006·Proceedings of the National Academy of Sciences of the United States of America·Garry MilmanRaphael Mechoulam
Sep 27, 2014·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·P S WongR E Roberts
May 4, 2004·The Journal of Physiology·Pál PacherGeorge Kunos
Apr 26, 2012·European Journal of Pharmacology·Jamie J HoppsMichael D Randall
Mar 28, 2009·European Journal of Pharmacology·Varadarajan SudhaharJohn D Imig
Dec 23, 2008·European Journal of Pharmacology·Amanda J Wheal, Michael D Randall
Mar 14, 2007·Pharmacology & Therapeutics·Katarzyna StarowiczVincenzo Di Marzo
Jul 6, 2004·The Journal of Pharmacy and Pharmacology·W-S Vanessa Ho, C Robin Hiley
Jul 6, 2005·British Journal of Pharmacology·Pouya MovahedEdward D Högestätt
Dec 3, 2003·British Journal of Pharmacology·Cristina ZorattiWolfgang F Graier
Oct 1, 2003·British Journal of Pharmacology·Ruth A Ross
Jun 6, 2003·British Journal of Pharmacology·W-S Vanessa Ho, C Robin Hiley
Apr 24, 2007·British Journal of Pharmacology·V E Mendizábal, E Adler-Graschinsky
Dec 18, 2013·British Journal of Pharmacology·Christopher Stanley, Saoirse E O'Sullivan
Nov 24, 2004·European Journal of Pharmacology·Visitación López-MirandaMaría Isabel Martín
Jul 25, 2006·Vascular Pharmacology·M T DannertV López-Miranda
Jul 31, 2014·British Journal of Pharmacology·Alexander I Bondarenko
Apr 3, 2012·European Journal of Pharmacology·Jamie J HoppsMichael D Randall
Jul 11, 2006·European Journal of Pharmacology·Mehdi GhasemiAhmad Reza Dehpour
Feb 11, 2004·British Journal of Pharmacology·Saoirse E O'SullivanMichael D Randall
May 19, 2004·British Journal of Pharmacology·Saoirse E O'SullivanMichael D Randall
Jun 12, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Youqin ChengRui Wang
Aug 13, 2003·Hypertension·Hugo C D SouzaMaria Cristina O Salgado
Aug 24, 2005·Journal of Cardiovascular Pharmacology·Jens A WagnerGeorge Kunos
Jun 28, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Vahagn A OhanyanIan N Bratz
May 23, 2012·American Journal of Physiology. Heart and Circulatory Physiology·Giacinta GuariniIan N Bratz
Jul 1, 2014·Journal of Cardiovascular Pharmacology·Yan LuHope D Anderson
Mar 11, 2003·The Journal of Pharmacology and Experimental Therapeutics·Y ZhangL J Janssen
Feb 28, 2003·Molecular Pharmacology·László OffertálerGeorge Kunos
May 8, 2004·British Journal of Pharmacology·Michael D RandallSaoirse O'Sullivan
Oct 27, 2004·Journal of Cardiovascular Pharmacology·John C AshtonPaul F Smith

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.